On Wednesday, September 11, Astherna’s Chief Scientific Officer, Prof. Rob Collin, will open Day 1 of the 5th Gene Therapy for Ophthalmic Disorders Summit in Boston with a presentation on “Advancing ASO Therapies for Ophthalmic Disorders.” Rob will highlight the potential of antisense oligonucleotides (ASOs) for treating eye disorders and discuss innovative methods and strategies for developing these highly specific therapies.
This is a great opportunity to hear about the latest breakthroughs in ophthalmic RNA therapy from Astherna.
Related Posts
